KMTS
Kestra Medical Technologies, Ltd.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+59/100
Last price
27.10
▼ 1.24 (4.38%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
28.34
Day high
29.24
Day low
27.06
Volume
262.25K
Market cap
$1.61B
P/E (TTM)
—
52W range
17.34 – 30.00
Trailing performance
Returnvs SPY
1W
-4.78%
-6.7%
1M
+6.11%
+5.0%
3M
+1.12%
-3.4%
6M
+39.05%
+20.9%
YTD
+2.19%
-12.1%
1Y
+9.19%
-7.2%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KMTS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+288.97K
Net buying
Buy transactions
18
595.90K shares
Sell transactions
21
306.93K shares
Net transactions
+39
Buys less sells
Sell : buy shares
0.5 : 1
Mixed
Insider-held shares
3.13M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 30, 26 | COHEN RAYMOND W Director |
SELL | 3.33K | $97.50K | Direct |
| Sep 21, 26 | KWO ELIZABETH Director |
SELL | 4.01K | $97.27K | Direct |
| Sep 9, 26 | COHEN RAYMOND W Director |
STOCK | 7.22K | $0 | Direct |
| Sep 9, 26 | LADONE MARY KAY Director |
STOCK | 7.22K | $0 | Direct |
| Sep 9, 26 | SCHWARTZ JEFFREY LAWRENCE Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 7.22K | $0 | Direct |
| Sep 9, 26 | KWO ELIZABETH Director |
STOCK | 7.22K | $0 | Direct |
| Sep 9, 26 | REILLY KEVIN C Director |
STOCK | 7.22K | $0 | Direct |
| Sep 9, 26 | HANLEY CONOR Director |
STOCK | 7.22K | $0 | Direct |
| Sep 8, 26 | LADONE MARY KAY Director |
SELL | 3.91K | $98.46K | Direct |
| Sep 8, 26 | SCHWARTZ JEFFREY LAWRENCE Director and Beneficial Owner of more than 10% of a Class of Security |
SELL | 3.89K | $97.94K | Direct |
| Sep 8, 26 | REILLY KEVIN C Director |
SELL | 2.93K | $73.68K | Direct |
| Sep 8, 26 | HANLEY CONOR Director |
SELL | 5.69K | $143.78K | Direct |
| Aug 17, 26 | WEBSTER BRIAN DANIEL Chief Executive Officer |
SELL | 15.00K | $412.18K | Direct |
| Aug 7, 26 | MAHBOOB VASEEM Chief Financial Officer |
SELL | 26.29K | $680.38K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
COHEN RAYMOND W |
Director | 54.79K | Sale |
FORD ALFRED J. JR |
Officer | 99.56K | Sale |
HANLEY CONOR |
Director | 13.49K | Stock Award(Grant) |
KWO ELIZABETH |
Director | 14.12K | Sale |
LADONE MARY KAY |
Director | 44.72K | Stock Award(Grant) |
MAHBOOB VASEEM |
Chief Financial Officer | 60.61K | Sale |
MORAN TIMOTHY P. |
Officer | 66.34K | Sale |
SCHWARTZ JEFFREY LAWRENCE |
Director and Beneficial Owner of more than 10% of a Class of Security | 25.19M | Stock Award(Grant) |
UMBERGER TRACI S |
General Counsel | 195.82K | Sale |
WEBSTER BRIAN DANIEL |
Chief Executive Officer | 460.21K | Sale |
Fundamentals
Market cap$1.61B
Enterprise value$1.49B
Revenue (TTM)$106.73M
Gross profit$57.51M
EBITDA$-134.18M
Net income$-149.87M
EPS (TTM)$-2.67
Free cash flow$-72.03M
Total cash$198.91M
Total debt$76.45M
Book value / share$3.75
Shares outstanding59.56M
Float33.70M
Short % of float11.13%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-13.19
PEG ratio—
Price / sales—
Price / book7.22
EV / revenue13.98
EV / EBITDA-11.12
Gross margin53.89%
Operating margin-121.59%
Profit margin-140.43%
Return on equity-73.73%
Return on assets-29.23%
Debt / equity34.38
Current ratio4.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $95.13M | $59.81M | $27.81M | $7.63M | +59.0% |
| Operating revenue | $95.13M | $59.81M | $27.81M | $7.63M | +59.0% |
| Cost of revenue | $46.26M | $35.60M | $27.45M | $18.28M | +29.9% |
| Gross profit | $48.86M | $24.21M | $362.00K | -$10.65M | +101.8% |
| Research & development | $19.48M | $15.65M | $15.49M | $15.76M | +24.5% |
| Selling, general & admin | $164.12M | $114.94M | $69.94M | $54.01M | +42.8% |
| Total operating expense | $183.60M | $130.59M | $85.42M | $69.77M | +40.6% |
| Operating income | -$134.74M | -$106.38M | -$85.06M | -$80.42M | -26.7% |
| Net interest income | $805.00K | -$4.54M | -$6.23M | -$5.63M | +117.8% |
| Pre-tax income | -$131.32M | -$113.68M | -$94.10M | -$84.22M | -15.5% |
| Tax provision | $294.00K | $135.00K | $24.00K | $15.00K | +117.8% |
| Net income | -$131.61M | -$113.81M | -$94.12M | -$84.24M | -15.6% |
| Net income to common | -$131.61M | -$126.14M | -$100.84M | -$86.74M | -4.3% |
| Basic EPS | -2.43 | -5.13 | -5.07 | -4.36 | +52.6% |
| Diluted EPS | -2.43 | -5.13 | -5.07 | -4.36 | +52.6% |
| EBIT | -$123.77M | -$105.94M | -$87.87M | -$78.59M | -16.8% |
| EBITDA | -$115.06M | -$97.98M | -$76.31M | -$73.74M | -17.4% |
| Basic shares | 54.18M | 24.58M | 19.89M | 19.89M | +120.4% |
| Diluted shares | 54.18M | 24.58M | 19.89M | 19.89M | +120.4% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $99.71M | $237.59M | $8.25M | $14.81M | -58.0% |
| Cash & short-term investments | $196.43M | $237.59M | $8.25M | $14.81M | -17.3% |
| Accounts receivable | $14.54M | $8.08M | $2.00M | $0 | +80.0% |
| Inventory | $6.71M | $6.57M | $3.29M | $2.11M | +2.0% |
| Total current assets | $222.36M | $255.33M | $14.91M | $18.42M | -12.9% |
| Property, plant & equipment | $62.45M | $36.91M | $28.39M | $16.72M | +69.2% |
| Total assets | $358.46M | $295.74M | $45.95M | $38.66M | +21.2% |
| Total current liabilities | $50.37M | $37.98M | $32.97M | $36.74M | +32.6% |
| Current debt | — | — | — | $20.45M | — |
| Long-term debt | $42.65M | $41.10M | $42.54M | $17.32M | +3.8% |
| Total debt | $46.79M | $44.31M | $45.17M | $39.13M | +5.6% |
| Total liabilities | $98.81M | $90.34M | $255.33M | $156.23M | +9.4% |
| Retained earnings | -$651.86M | -$520.25M | -$406.44M | -$312.31M | -25.3% |
| Shareholder equity | $259.66M | $205.41M | -$209.38M | -$117.58M | +26.4% |
| Working capital | $171.99M | $217.35M | -$18.06M | -$18.32M | -20.9% |
| Net tangible assets | $259.66M | $205.41M | -$209.38M | -$117.58M | +26.4% |
| Shares issued | 58.38M | 51.35M | 49.53M | 49.53M | +13.7% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$131.61M | -$113.81M | -$94.12M | -$84.24M | -15.6% |
| Depreciation & amortisation | $8.71M | $7.97M | $11.56M | $4.86M | +9.3% |
| Stock-based compensation | $33.64M | $24.27M | $1.49M | $1.21M | +38.6% |
| Change in working capital | $1.78M | -$6.20M | $3.89M | $1.30M | +128.6% |
| Operating cash flow | -$81.70M | -$77.61M | -$72.23M | -$69.64M | -5.3% |
| Capital expenditure | -$35.42M | -$23.59M | -$12.51M | -$15.46M | -50.1% |
| Investing cash flow | -$203.28M | -$23.31M | -$12.23M | -$15.46M | -772.1% |
| Dividends paid | -$323.00K | -$1.65M | -$799.00K | -$671.00K | +80.5% |
| Financing cash flow | $147.09M | $330.26M | $77.72M | $96.11M | -55.5% |
| Free cash flow | -$117.12M | -$101.20M | -$84.75M | -$85.10M | -15.7% |
| End cash position | $100.04M | $237.93M | $8.58M | $15.32M | -58.0% |
| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $30.97M | $28.64M | $24.55M | $22.57M | $19.37M | +8.1% |
| Operating revenue | $30.97M | $28.64M | $24.55M | $22.57M | $19.37M | +8.1% |
| Cost of revenue | $13.47M | $12.96M | $11.65M | $11.14M | $10.52M | +4.0% |
| Gross profit | $17.50M | $15.68M | $12.91M | $11.42M | $8.85M | +11.6% |
| Research & development | $6.80M | $5.63M | $4.97M | $4.88M | $4.00M | +20.6% |
| Selling, general & admin | $48.36M | $49.39M | $42.70M | $38.30M | $33.73M | -2.1% |
| Total operating expense | $55.16M | $55.03M | $47.67M | $43.18M | $37.73M | +0.2% |
| Operating income | -$37.66M | -$39.34M | -$34.77M | -$31.75M | -$28.88M | +4.3% |
| Net interest income | $196.00K | $382.00K | $275.00K | -$105.00K | $255.00K | -48.7% |
| Pre-tax income | -$44.04M | -$38.64M | -$34.13M | -$32.75M | -$25.79M | -14.0% |
| Tax provision | $50.00K | $192.00K | $35.00K | $34.00K | $33.00K | -74.0% |
| Net income | -$44.09M | -$38.84M | -$34.17M | -$32.78M | -$25.83M | -13.5% |
| Net income to common | -$44.09M | -$38.84M | -$34.17M | -$32.78M | -$25.83M | -13.5% |
| Basic EPS | -0.75 | -0.67 | -0.61 | -0.64 | -0.50 | -11.9% |
| Diluted EPS | -0.75 | -0.67 | -0.61 | -0.64 | -0.50 | -11.9% |
| EBIT | -$42.11M | -$36.80M | -$32.24M | -$30.85M | -$23.88M | -14.4% |
| EBITDA | -$39.44M | -$34.47M | -$30.26M | -$28.48M | -$21.85M | -14.4% |
| Basic shares | 58.57M | 58.40M | 55.85M | 51.38M | 51.30M | +0.3% |
| Diluted shares | 58.57M | 58.40M | 55.85M | 51.38M | 51.30M | +0.3% |
| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $68.56M | $99.71M | $291.32M | $175.42M | $201.21M | -31.2% |
| Cash & short-term investments | $198.91M | $196.43M | $291.32M | $175.42M | $201.21M | +1.3% |
| Accounts receivable | $15.41M | $14.54M | $12.71M | $10.41M | $9.25M | +5.9% |
| Inventory | $7.44M | $6.71M | $6.83M | $6.92M | $6.80M | +10.9% |
| Total current assets | $226.27M | $222.36M | $314.06M | $195.41M | $220.69M | +1.8% |
| Property, plant & equipment | $66.92M | $62.45M | $57.22M | $47.89M | $42.42M | +7.1% |
| Total assets | $347.36M | $358.46M | $379.34M | $246.70M | $266.30M | -3.1% |
| Total current liabilities | $48.27M | $50.37M | $42.93M | $35.76M | $32.26M | -4.2% |
| Long-term debt | $72.50M | $42.65M | $42.26M | $41.87M | $41.49M | +70.0% |
| Total debt | $76.45M | $46.79M | $46.55M | $44.80M | $44.59M | +63.4% |
| Total liabilities | $125.00M | $98.81M | $91.35M | $82.62M | $82.14M | +26.5% |
| Retained earnings | -$695.95M | -$651.86M | -$613.03M | -$578.86M | -$546.08M | -6.8% |
| Shareholder equity | $222.36M | $259.66M | $287.99M | $164.08M | $184.16M | -14.4% |
| Working capital | $178.00M | $171.99M | $271.13M | $159.66M | $188.44M | +3.5% |
| Net tangible assets | $222.36M | $259.66M | $287.99M | $164.08M | $184.16M | -14.4% |
| Shares issued | 59.27M | 58.38M | 58.35M | 51.45M | 51.35M | +1.5% |
| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$44.09M | -$38.84M | -$34.17M | -$32.78M | -$25.83M | -13.5% |
| Depreciation & amortisation | $2.66M | $2.33M | $1.98M | $2.37M | $2.03M | +14.6% |
| Stock-based compensation | $9.52M | $10.30M | $10.11M | $8.65M | $4.58M | -7.6% |
| Change in working capital | -$7.50M | $4.93M | $2.12M | $711.00K | -$5.98M | -252.2% |
| Operating cash flow | -$32.30M | -$18.72M | -$18.37M | -$18.34M | -$26.27M | -72.5% |
| Capital expenditure | -$8.34M | -$9.66M | -$9.99M | -$7.50M | -$8.27M | +13.8% |
| Investing cash flow | -$21.35M | -$172.71M | -$14.92M | -$7.42M | -$8.23M | +87.6% |
| Dividends paid | -$172.00K | -$298.00K | -$25.00K | $0 | $0 | +42.3% |
| Financing cash flow | $22.50M | -$185.00K | $149.18M | -$27.00K | -$1.88M | +12,259.5% |
| Free cash flow | -$40.63M | -$28.39M | -$28.35M | -$25.84M | -$34.54M | -43.1% |
| End cash position | $68.89M | $100.04M | $291.65M | $175.76M | $201.55M | -31.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | -0.63 | -0.46 | +26.7% |
| Apr 2026 | -0.58 | -0.49 | +15.8% |
| Jan 2026 | -0.60 | -0.40 | +32.6% |
| Oct 2025 | -0.56 | -0.45 | +19.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.61 | 2 | $32.03M | +41.9% |
| Next quarter | -0.58 | 2 | $35.43M | +44.3% |
| Current year | -2.45 | 2 | $140.91M | +48.1% |
| Next year | -2.06 | 2 | $195.90M | +39.0% |
Analyst targets & ownership
Mean target$30.29
High target$32.00
Low target$28.00
Implied upside11.76%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy2 / 5
Hold1
Sell / Strong sell0 / 0
Held by insiders5.25%
Held by institutions101.75%
Institutions holding175
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
27.33
-0.83% from price
SMA 20
25.84
+4.89% from price
SMA 50
25.97
+4.34% from price
SMA 100
24.11
+12.39% from price
SMA 200
23.61
+14.80% from price
EMA 12
27.02
+0.31% from price
EMA 26
26.36
+2.81% from price
EMA 50
25.72
+5.36% from price
RSI (14)
54.2
Neutral
MACD (12,26,9)
0.66
Hist 0.21
ATR (14)
1.38
5.08% of price
Realised vol 30D
48.5%
Annualised
Bollinger upper
29.34
20, 2σ
Bollinger lower
22.34
20, 2σ
50 / 200 cross
Golden
25.97 vs 23.61
Trend bias
Above 200
+14.80%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.55
More volatile than market
Correlation to SPY
0.32
Loosely linked
Realised vol 30D
48.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-36.2%
Peak to trough
Max drawdown 5Y
-43.7%
Peak to trough
ATR 14
1.38
5.08% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
3.12M
Prior 3.02M
Change vs prior
+3.6%
Shorts adding
% of float
11.13%
Elevated
% of shares out
5.24%
Against total outstanding
Days to cover
10.1
Crowded exit
Float
33.70M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 15, 26 | BTIG | MAINTAINED | Buy | Buy |
| Sep 2, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 10, 26 | JP Morgan | INITIATED | — | Overweight |
| Jul 21, 26 | Oppenheimer | INITIATED | — | Perform |
| Jul 15, 26 | BTIG | MAINTAINED | Buy | Buy |
| Apr 9, 26 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Apr 7, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 25, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 18, 26 | BTIG | MAINTAINED | Buy | Buy |
| Dec 15, 25 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Dec 12, 25 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Dec 12, 25 | Piper Sandler | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-09-10
Proxy Statements
DEFA14A · 2026-07-28
Periodic Financial Reports
10-K · 2026-07-14
Offering Registrations
S-3ASR · 2026-04-01
Offering Registrations
S-8 · 2026-03-18
Corporate Changes & Voting Matters
8-K · 2026-03-17
Corporate Changes & Voting Matters
8-K · 2025-12-11
Headlines
Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies
GlobeNewswire · 6d ago
Kestra Medical Technologies (KMTS) Could Be 17% Undervalued Following Raised Revenue Outlook
Simply Wall St. · 15d ago
Kestra Medical (KMTS) Raises Outlook. Can Better Reimbursement Support Scale?
Insider Monkey · 20d ago
KESTRA MEDICAL TECHNOLOGIES, LTD. Q1 2027 Earnings Call Summary
Moby · 22d ago
Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60% as ...
GuruFocus.com · 22d ago
Kestra Medical Technologies Q1 Earnings Call Highlights
MarketBeat · 23d ago
Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates
Zacks · 23d ago
Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
GlobeNewswire · 23d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.